Systemic lupus erythematosus (sle) is a chronic inflammatory autoimmune disease of unknown etiology. The prevalence of SLE is 1:1,000; thus, most primary care physicians will not have sufficient experience in the management of moderate or severe life-threatening disease. Patients with SLE develop distinct immunologic abnormalities, in particular, antinuclear, anticytoplasmic, and antiphospholipid antibodies.
Systemic lupus erythematosus (sle) is a chronic inflammatory autoimmune disease of unknown etiology. The prevalence of SLE is 1:1,000; thus, most primary care physicians will not have sufficient experience in the management of moderate or severe life-threatening disease. Patients with SLE develop distinct immunologic abnormalities, in particular, antinuclear, anticytoplasmic, and antiphospholipid antibodies.
Systemic lupus erythematosus (sle) is a chronic inflammatory autoimmune disease of unknown etiology. The prevalence of SLE is 1:1,000; thus, most primary care physicians will not have sufficient experience in the management of moderate or severe life-threatening disease. Patients with SLE develop distinct immunologic abnormalities, in particular, antinuclear, anticytoplasmic, and antiphospholipid antibodies.